Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. September 2025 08:43 ET | Quelle: ADvantage Therapeutics, Inc.

UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
26. September 2025 06:52 ET | Quelle: ADvantage Therapeutics, Inc.

ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic

ADvantage Therapeutics Awarded $2.5 milion NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
09. September 2024 10:01 ET | Quelle: ADvantage Therapeutics, Inc.

ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan

MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a leading clinical-stage biotechnology company dedicated to the advancement of innovative therapies for Alzheimer's disease,...
05. April 2023 08:35 ET | Quelle: Advantage Therapeutics Inc.

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...